RxDoctor Payments Data

Kelly Drusen, NP

Family · McAlester, OKNPI 1063790681

Payments from drug & device makers

$929in general payments, 2019–2025

Across 51 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$226
  • GSK$217
  • Novo Nordisk$162
  • Pfizer$91
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$72
  • Dexcom, Inc.$36
  • plus $127 from 7 others

What the payments were for

  • Food & beverage$929100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$929 in reported general payments places this provider in the 65th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$137,586
Medicare patients
384
Services billed
3,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$123,191
EliquisApixaban124$104,191
RybelsusSemaglutide19$44,336
JanuviaSitagliptin Phosphate25$39,459
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$36,251
Breo ElliptaFluticasone/Vilanterol76$33,649
Tresiba Flextouch U-200Insulin Degludec16$22,115
MounjaroTirzepatide17$20,767
FarxigaDapagliflozin Propanediol17$20,171
JardianceEmpagliflozin14$17,765
Tresiba Flextouch U-100Insulin Degludec12$12,717
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$9,625
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,754
SymbicortBudesonide/Formoterol Fumarate29$6,547
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$5,713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$162$167,52786 claims
PfizerEliquis$91$104,191124 claims
GSKTrelegy Ellipta, Breo Ellipta$217$69,900121 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$30$33,47157 claims
Boehringer IngelheimJardiance$13$17,76514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,026 family providers in Oklahoma.

Other family in McAlester

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →